Total Payments
$96,623
2024 Payments
$3,550
Companies
10
Transactions
81
Medicare Patients
508
Medicare Billing
$85,917
Payment Breakdown by Category
Other$57,330 (59.3%)
Research$20,163 (20.9%)
Consulting$13,379 (13.8%)
Travel$4,107 (4.3%)
Food & Beverage$1,623 (1.7%)
Education$21.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,180 | 22 | 59.2% |
| Unspecified | $20,163 | 13 | 20.9% |
| Consulting Fee | $13,379 | 12 | 13.8% |
| Travel and Lodging | $4,107 | 10 | 4.3% |
| Food and Beverage | $1,623 | 20 | 1.7% |
| Honoraria | $150.00 | 1 | 0.2% |
| Education | $21.27 | 3 | 0.0% |
Payments by Type
General
$76,460
68 transactions
Research
$20,163
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46,643 | 35 | $0 (2022) |
| ABBVIE INC. | $30,909 | 21 | $0 (2024) |
| Celgene Corporation | $15,391 | 14 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $3,096 | 2 | $0 (2017) |
| Seattle Genetics, Inc. | $201.67 | 3 | $0 (2018) |
| Alexion Pharmaceuticals, Inc. | $150.00 | 1 | $0 (2021) |
| Kite Pharma, Inc. | $114.41 | 1 | $0 (2018) |
| Bioventus LLC | $64.15 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $36.70 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $17.73 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,550 | 3 | ABBVIE INC. ($3,550) |
| 2023 | $1,688 | 1 | AbbVie Inc. ($1,688) |
| 2022 | $26,884 | 17 | E.R. Squibb & Sons, L.L.C. ($20,084) |
| 2021 | $10,279 | 9 | Celgene Corporation ($9,579) |
| 2020 | $12,087 | 10 | AbbVie Inc. ($8,712) |
| 2019 | $13,126 | 11 | E.R. Squibb & Sons, L.L.C. ($8,837) |
| 2018 | $6,303 | 9 | AbbVie, Inc. ($4,950) |
| 2017 | $22,707 | 21 | E.R. Squibb & Sons, L.L.C. ($16,722) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,087.50 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome • Category: ONCOLOGY | ||||||
| 07/22/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,450.00 | General |
| Category: ONCOLOGY | ||||||
| 01/08/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,012.50 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) • Category: ONCOLOGY | ||||||
| 07/28/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,687.50 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) • Category: ONCOLOGY | ||||||
| 12/09/2022 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,687.50 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome • Category: ONCOLOGY | ||||||
| 11/29/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 11/17/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Travel and Lodging | Cash or cash equivalent | $813.41 | General |
| Category: Oncology | ||||||
| 11/17/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $103.33 | General |
| Category: Oncology | ||||||
| 11/09/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 11/02/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $120.69 | General |
| Category: Oncology | ||||||
| 09/08/2022 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,012.50 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome • Category: ONCOLOGY | ||||||
| 08/04/2022 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome • Category: ONCOLOGY | ||||||
| 05/17/2022 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Hematology | ||||||
| 05/04/2022 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $807.91 | General |
| Category: Hematology | ||||||
| 05/04/2022 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $55.51 | General |
| Category: Hematology | ||||||
| 04/13/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2022 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,650.00 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome • Category: ONCOLOGY | ||||||
| 03/08/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 02/23/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Travel and Lodging | Cash or cash equivalent | $302.78 | General |
| Category: Oncology | ||||||
| 02/22/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 02/15/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 11/09/2021 | Celgene Corporation | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Hematology | ||||||
| 11/09/2021 | Celgene Corporation | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Hematology | ||||||
| 10/15/2021 | Celgene Corporation | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 09/22/2021 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | Honoraria | Cash or cash equivalent | $150.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | ABBVIE INC. | $6,788 | 5 |
| M16-043 | AbbVie, Inc. | $6,738 | 2 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) | AbbVie Inc. | $1,688 | 1 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (17007) | Celgene Corporation | $1,144 | 1 |
| An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) (17004) | Celgene Corporation | $1,144 | 1 |
| M15-656 | AbbVie Inc. | $1,100 | 1 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) | ABBVIE INC. | $1,013 | 1 |
| A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) | ABBVIE INC. | $550.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 69 | 100 | $40,307 | $8,355 |
| 2021 | 7 | 204 | 400 | $153,388 | $36,708 |
| 2020 | 9 | 235 | 566 | $162,950 | $40,855 |
Total Patients
508
Total Services
1,066
Medicare Billing
$85,917
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 30 | 51 | $24,480 | $5,119 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 39 | 49 | $15,827 | $3,236 | 20.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 113 | $54,579 | $13,123 | 24.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 99 | $33,066 | $8,366 | 25.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 104 | $33,800 | $7,669 | 22.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $10,944 | $2,737 | 25.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 13 | $8,489 | $2,047 | 24.1% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 17 | 25 | $6,350 | $1,600 | 25.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 27 | 28 | $6,160 | $1,167 | 18.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 148 | $49,136 | $12,639 | 25.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 51 | 139 | $35,028 | $8,491 | 24.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 22 | $14,190 | $3,689 | 26.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 61 | $14,091 | $3,679 | 26.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 57 | 88 | $14,432 | $3,187 | 22.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 24 | 35 | $12,460 | $3,105 | 24.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $9,720 | $2,532 | 26.1% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 22 | 33 | $8,349 | $2,090 | 25.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 22 | $5,544 | $1,443 | 26.0% |
About Dr. John Godwin, MD
Dr. John Godwin, MD is a Hematology & Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1700863677.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Godwin, MD has received a total of $96,623 in payments from pharmaceutical and medical device companies, with $3,550 received in 2024. These payments were reported across 81 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($57,180).
As a Medicare-enrolled provider, Godwin has provided services to 508 Medicare beneficiaries, totaling 1,066 services with total Medicare billing of $85,917. Data is available for 3 years (2020–2022), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Portland, OR
- Active Since 12/30/2005
- Last Updated 01/18/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700863677
Products in Payments
- EMPLICITI (Biological) $26,559
- VENCLEXTA (Drug) $21,300
- ONUREG (Drug) $18,660
- REBLOZYL (Biological) $13,402
- Venclexta (Drug) $9,609
- Aliqopa (Drug) $3,000
- JCAR017 (Drug) $2,288
- ADCETRIS (Biological) $201.67
- Ultomiris (Drug) $150.00
- Yescarta (Drug) $114.41
- Non-Covered $96.13
- IMBRUVICA (Drug) $36.70
- RYDAPT (Drug) $17.73
- Luspatercept (Drug) $8.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Portland
Brian Druker, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Dr. Jay Andersen, M.d, M.D
Hematology & Oncology — Payments: $480,702
Hematology & Oncology $480,702
Rachel Sanborn, Md, MD
Hematology & Oncology — Payments: $322,427
Hematology & Oncology $322,427
Richard Maziarz, Md, MD
Hematology & Oncology — Payments: $246,109
Hematology & Oncology $246,109
Tibor Kovacsovics, Md, MD
Hematology & Oncology — Payments: $245,023
Hematology & Oncology $245,023
Dr. Rom Leidner, Md, MD
Hematology & Oncology — Payments: $79,796
Hematology & Oncology $79,796